WORLD-TECHNOLOGY-GAMES
The World Technology Games (WTG), a groundbreaking global competition in innovation, technology and science, announced its inaugural event for Q3 2026. The annual, five-day event will include Competitions, a Festival and a Leadership Summit. The Games will celebrate and elevate advancements across Life, Earth, Data and Industrial Sciences, through unifying themes like sustainability and AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725287146/en/
World Technology Games CEO Alexander Brown and Gabriela Ramos, Assistant Director-General for the Social and Human Sciences of UNESCO, at The UNESCO “Change the Game” Ministerial Sport Conference in Paris on July 23, 2024. (Photo: Business Wire)
“We built the World Technology Games to inspire people around the world to create technological solutions for today’s most formidable challenges,” said Alexander Brown, CEO of the World Technology Games. “Our first-of-its-kind international event will convene brilliant minds from diverse backgrounds to compete, collaborate, and catalyze change at global scale.”
The World Technology Games were showcased by Mr. Brown at the UNESCO “Change the Game” Global Sport Conference as France hosts the 2024 Olympic Games. The WTG underscored its commitment to support key UN Sustainable Development Goals and to UNESCO’s vision of building multilateral collaboration on education, science, culture, communication and information.
The WTG will honor the ambition, competitive spirit and ingenuity that drive today’s greatest technological contributions. An international cohort of scientists, engineers and innovators will unite for two categories of cutting-edge competitions that aim to entertain and empower people through technology, passion and purpose. “Spotlights” are organized in partnership with established leagues, including support from the Indy Autonomous Challenge and the Global Esports Federation. Unique to the Games, “Originals” are characterized by scientific rigor, real-world application and technological acumen, including culinary creativity, sustainable fashion design, robotics and more.
Through the live event and digital content, the WTG targets a global audience of more than 1.6 billion people who consider technology an essential component of their daily lives. With a focus on engaging Gen T – the nearly 700 million individuals globally who are poised to shape the future of technology – the Games will be amplified by a multi-channel approach distributed across social, digital, podcasts, streaming platforms and linear broadcast.
The WTG is led by Alexander Brown. Mr. Brown has a proven track record of building and growing businesses at a global scale including serving as Managing Director of ESPN Asia and ESPN Star Sports, as well as leadership positions with the NBA, Univision and One World Sports. Brown also served as President & CEO of CNBC Asia. Chairman of the Board, Paul J. Foster is CEO & Member of the Board for the Global Esports Federation and focuses on integrating innovative technology with social impact. He brings more than 20 years of experience in the Olympic Movement, an extensive tenure at the International Olympic Committee and global strategic consulting. The WTG is championed by an International Advisory Council of multidisciplinary experts from more than 20 countries who have spearheaded the growth of global companies and organizations across science, technology, diplomacy, entertainment, and finance.
The Games will also feature an immersive festival and thought leadership summit. The World Technology Festival will celebrate the intersection of technology, art and culture through exhibitions, product showcases and workshops. The World Technology Summit will convene industry experts with keynote speeches, debates and expert panels to explore future trends and the transformative potential of technology.
The inaugural host city selection has begun, with cities worldwide encouraged to submit expressions of interest through September 2024. For more information on the World Technology Games please visit: https://worldtechnology.games/.
About the World Technology Games:
The World Technology Games (WTG) is a global, first-of-its-kind competition celebrating human ingenuity in Life, Earth, Data and Industrial sciences. Set to debut in 2026, the annual five-day event will convene scientists, engineers and innovators from around the world for a series of cutting-edge competitions, a festival and a leadership summit that address humanity’s greatest challenges through technology, passion and purpose. Led by an accomplished leadership team of global multidisciplinary experts, the WTG will empower and entertain a worldwide audience by honoring the unheralded, yet brilliant minds behind today’s greatest advancements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725287146/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom